VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
(Hong Kong, December 15 , 2022) A biopharmaceutical company in China for the development and commercialization of next-generation tumor immunotherapy drugs - 3D Medicines Inc. (“ 3D Medicines” or the “Company”, Stock Code: 1244.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange”) today.
Beijing, China October 8, 2022- 3D Medicines Inc. announced today that the subject has been dosed in the Phase I clinical trial for 3D189 (also known as galinpepimut-S, or GPS), which is the first clinical trial in China for this product to assess the safety and immunogenicity of 3D189 in patients with hematological malignancies. The first dosing of the first participant was completed. 3D Medicines holds the exclusive license from SELLAS to develop, manufacture and commercialize 3D189 in China, Hong Kong, Macau and Taiwan region for all therapeutic and other diagnostic uses.
Beijing, China April 18, 2022 - 3D Medicines Inc. (3D Medicines) announces that the multi-center, open-label phase Ib/II clinical trial of Batiraxcept (3D229) in combination with envafolimab or lenvatinib in patients with advanced solid tumor was approved by China’s National Medical Products Administration (NMPA).
Beijing，April 6，2022 - 3D Medicines Inc. (the “Company”), today announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’s galinpepimut-s (“GPS”), has been approved by China’s National Medical Products Administration (“NMPA”) to evaluate safety and immunogenicity of 3D189 in Chinese patients with hematological malignancies.
Beijing China, March 15, 2022 - 3D Medicines, a commercial-stage, oncology-focused Bio-pharmaceutical company, and Merck, a global leading science and technology company, today announced a partnership on clinical research. Under the collaboration, a clinical trial is designed to evaluate the combination of envafolimab, the world’s subcutaneously injected PD-L1 antibody drug, and Erbitux® (cetuximab), an epidermal growth factor receptor (EGFR) inhibitor in the treatment of patients with RAS/BRAF wild-type, non-MSI-H/pMMR metastatic colorectal cancer (mCRC) who previously failed the treatment with fluorouracil, oxaliplatin, irinotecan and bevacizumab